Predicting bortezomib-related severe neurologic adverse events by measuring proteasome activity in PBMCs.

Yukiko Cho(Ibaraki Prefectural Central Hospital), Daisuke Kudo(Barrow Neurological Institute), Mitsuo Hori(Ibaraki Prefectural Central Hospital), Ikuyo Ota(National Hospital Organization Mito Medical Center), Takuya Komeno(National Hospital Organization Mito Medical Center), Yukitaka Katsura(National Hospital Organization Mito Medical Center), Katsuhiro Sasaki(Kyoto University), Seiichi Shimizu(Tsuchiura Kyodo General Hospital), Hiroshi Kojima(Ibaraki Prefectural Central Hospital), Keiji Tanaka(Tokyo Metropolitan Institute of Medical Science), Yasushi Okoshi(Ibaraki Prefectural Central Hospital), Harumi Y. Mukai, Atsushi Shinagawa(Hitachi General Hospital), Chikashi Yoshida(National Hospital Organization Mito Medical Center)
Journal of Clinical Oncology
May 20, 2012
Cited by 0


Related Papers